Philipp Hendrix1, Yvonne Dzierma1,2, Benedikt W Burkhardt1, Andreas Simgen3, Gudrun Wagenpfeil4, Christoph J Griessenauer5,6, Sebastian Senger1, Joachim Oertel1. 1. Department of Neurosurgery, Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg, Germany. 2. Department of Radiation Oncology, Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg, Germany. 3. Department of Neuroradiology, Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg, Germany. 4. Institute for Medical Biometry, Epidemiology and Medical Informatics (IMBEI), Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg, Germany. 5. Department of Neurosurgery, Geisinger, Danville, Pennsylvania. 6. Research Institute of Neurointervention, Paracelsus Medical University, Salzburg, Austria.
Abstract
BACKGROUND: Navigated transcranial magnetic stimulation (nTMS) is an established, noninvasive tool to preoperatively map the motor cortex. Despite encouraging reports from few academic centers with vast nTMS experience, its value for motor-eloquent brain surgery still requires further exploration. OBJECTIVE: To further elucidate the role of preoperative nTMS in motor-eloquent brain surgery. METHODS: Patients who underwent surgery for a motor-eloquent supratentorial glioma or metastasis guided by preoperative nTMS were retrospectively reviewed. The nTMS group (n = 105) was pair-matched to controls (non-nTMS group, n = 105). Gross total resection (GTR) and motor outcome were evaluated. Subgroup analyses including survival analysis for WHO III/IV glioma were performed. RESULTS: GTR was significantly more frequently achieved in the entire nTMS group compared to the non-nTMS group (P = .02). Motor outcome did not differ (P = .344). Bootstrap analysis confirmed these findings. In the metastases subgroup, GTR rates and motor outcomes were equal. In the WHO III/IV glioma subgroup, however, GTR was achieved more frequently in the nTMS group (72.3%) compared to non-nTMS group (53.2%) (P = .049), whereas motor outcomes did not differ (P = .521). In multivariable Cox-regression analysis, prolonged survival in WHO III/IV glioma was significantly associated with achievement of GTR and younger patient age but not nTMS mapping. CONCLUSION: Preoperative nTMS improves GTR rates without jeopardizing neurological function. In WHO III/IV glioma surgery, nTMS increases GTR rates that might translate into a beneficial overall survival. The value of nTMS in the setting of a potential survival benefit remains to be determined.
BACKGROUND: Navigated transcranial magnetic stimulation (nTMS) is an established, noninvasive tool to preoperatively map the motor cortex. Despite encouraging reports from few academic centers with vast nTMS experience, its value for motor-eloquent brain surgery still requires further exploration. OBJECTIVE: To further elucidate the role of preoperative nTMS in motor-eloquent brain surgery. METHODS:Patients who underwent surgery for a motor-eloquent supratentorial glioma or metastasis guided by preoperative nTMS were retrospectively reviewed. The nTMS group (n = 105) was pair-matched to controls (non-nTMS group, n = 105). Gross total resection (GTR) and motor outcome were evaluated. Subgroup analyses including survival analysis for WHO III/IV glioma were performed. RESULTS: GTR was significantly more frequently achieved in the entire nTMS group compared to the non-nTMS group (P = .02). Motor outcome did not differ (P = .344). Bootstrap analysis confirmed these findings. In the metastases subgroup, GTR rates and motor outcomes were equal. In the WHO III/IV glioma subgroup, however, GTR was achieved more frequently in the nTMS group (72.3%) compared to non-nTMS group (53.2%) (P = .049), whereas motor outcomes did not differ (P = .521). In multivariable Cox-regression analysis, prolonged survival in WHO III/IV glioma was significantly associated with achievement of GTR and younger patient age but not nTMS mapping. CONCLUSION: Preoperative nTMS improves GTR rates without jeopardizing neurological function. In WHO III/IV glioma surgery, nTMS increases GTR rates that might translate into a beneficial overall survival. The value of nTMS in the setting of a potential survival benefit remains to be determined.
Authors: Carolin Weiss Lucas; Andrea Maria Faymonville; Ricardo Loução; Catharina Schroeter; Charlotte Nettekoven; Ana-Maria Oros-Peusquens; Karl Josef Langen; N Jon Shah; Gabriele Stoffels; Volker Neuschmelting; Tobias Blau; Hannah Neuschmelting; Martin Hellmich; Martin Kocher; Christian Grefkes; Roland Goldbrunner Journal: Front Oncol Date: 2022-05-27 Impact factor: 5.738
Authors: Yvonne Dzierma; Michaela Schuermann; Patrick Melchior; Frank Nuesken; Joachim Oertel; Christian Rübe; Philipp Hendrix Journal: Front Oncol Date: 2021-02-26 Impact factor: 6.244
Authors: Michaela Schuermann; Yvonne Dzierma; Frank Nuesken; Joachim Oertel; Christian Rübe; Patrick Melchior Journal: Front Neurol Date: 2022-01-14 Impact factor: 4.003
Authors: Matthew Muir; Sarah Prinsloo; Hayley Michener; Jeffrey I Traylor; Rajan Patel; Ron Gadot; Dhiego Chaves de Almeida Bastos; Vinodh A Kumar; Sherise Ferguson; Sujit S Prabhu Journal: Cancers (Basel) Date: 2022-01-11 Impact factor: 6.639